Cymab ApS: Financial statements 2022
CVR: 39859173
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Cymab ApS (CVR 39859173) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -1,167,344 and a net result of DKK -1,541,246 compared with DKK -942,533 the year before. Equity in the 2022 report amounted to DKK -5,443,041. The company had 2 employees in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -1,167,344
- Profit/Loss
- DKK -1,541,246
- Equity
- DKK -5,443,041
- Total Assets
- DKK 5,165,662
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | -1.2M | -1.5M | -5.4M | 2 |
| 2021 | - | -567K | -943K | -3.9M | 1 |
| 2020 | 0 | -1.1M | -956K | -3M | - |
Official annual report
Keep an eye on Cymab ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Cymab ApS has published its annual report for 2021. Gross profit came to DKK -566,735, and the net result was DKK -942,533.
About Cymab ApS
Cymab ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ebumab ApS. The management consists of Johan Henrik Faber. The board consists of Hans Heugh Wandall (chair), Johan Henrik Faber, Mads Nikolaj Behrndt-Eriksen and Søren Erik Bjørn. The company is owned by Ebumab Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -5,463,240 and a net result of DKK -7,576,022 compared with DKK -4,627,624 the year before. Equity in the 2025 report amounted to DKK -20,227,476.